Istituto di Ricerche Farmacologiche "Mario Negri"

Fingerprint Dive into the research topics where Istituto di Ricerche Farmacologiche "Mario Negri" is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.

    • Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Profiles

    No photo of Diego Albani

    Diego Albani

    Person: Academic

    19992020
    No photo of Renzo Bagnati

    Renzo Bagnati

    Person: Academic

    19872019
    No photo of Claudia Balducci

    Claudia Balducci

    Person: Academic

    19962019

    Projects

    MARIO NEGRI - STUDI FARMACOLOGICI E CLINICI NELLE MALATTIE NEUROLOGICHE

    Ricerca, U.

    1/1/19 → 12/31/19

    Project: Other project

    MARIO NEGRI - Progetti Eranet e Ministero affari esteri e Progetti di rete

    Ricerca, U.

    1/1/19 → 12/31/19

    Project: Other project

    MARIO NEGRI - STUDI FARMACOLOGICI E CLINICI SU PATOLOGIE ASSOCIATE AD ESPOSIZIONE AMBIENTALE CON PARTICOLARE RIFERIMENTO ALLE MALATTIE RENALI CRONICHE

    Ricerca, U.

    1/1/19 → 12/31/19

    Project: Other project

    Research Output

    Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab

    Podestà, M. A., Gennarini, A., Portalupi, V., Rota, S., Alessio, M. G., Remuzzi, G. & Ruggenenti, P., 2020, In : Nephron. 144, 1, p. 30-35 6 p.

    Research output: Contribution to journal › Article

    • Analysis of BRCA1 and RAD51C promoter methylation in italian families at high-risk of breast and ovarian cancer

    Tabano, S., Azzollini, J., Pesenti, C., Lovati, S., Costanza, J., Fontana, L., Peissel, B., Miozzo, M. & Manoukian, S., Apr 2020, In : Cancers. 12, 4, 910.

    Research output: Contribution to journal › Article

    Open Access

    • Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial

    Petrelli, F., Labianca, R., Zaniboni, A., Lonardi, S., Galli, F., Rulli, E., Rosati, G., Corallo, S., Ronzoni, M., Cardellino, G. G., Mattioli, R., Mambrini, A., Ciuffreda, L., Banzi, M., Pusceddu, V., Maiello, E., Zampino, M., Zagonel, V., Marchetti, P., Corsi, D. & 3 others, Rimassa, L., Cinieri, S. & Sobrero, A., Apr 2020, In : JAMA oncology. 6, 4, p. 547-551 5 p.

    Research output: Contribution to journal › Article